BCL-2 inhibitors are used to treat chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and acute myeloid leukemia (AML). BCL-2 inhibitors work by blocking B-cell lymphoma 2 (BCL-2) proteins in cancer cells, which helps them survive. By inhibiting this protein, BCL-2 inhibitors promote the death of cancer cells. Venclexta (venetoclax) is a main example, and it comes as an oral tablet.